BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
May 11 2021 - 6:30AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
(TSX-V:BCT) (“BriaCell” or the “Company”), a
clinical-stage biotechnology company specializing in targeted
immunotherapies for advanced breast cancer, today
announced that Dr. William V. Williams, President & CEO of
BriaCell, is scheduled to participate in the following virtual
conferences:
- Benzinga Global Small Cap
Investor Conference: May 13-14, 2021
- Dr. Williams will deliver his
corporate presentation at 12:20pm ET on May 13, 2021.
- Dr. Williams will also participate
in a panel discussion titled “Investing Post COVID – Back to the
Fundamentals” at 11:50am ET on May 13, 2021. The panel will discuss
healthcare investing in the post COVID world.
- Investors may request one-on-one
meetings with Dr. Williams.
- Investors may register for the
conference here:
https://www.benzinga.com/events/small-cap/global/.
- Q2 Investor Summit: May
17-18, 2021
- Dr. Williams will deliver his
corporate presentation at 2:00pm ET on May 17, 2021.
- Investors may request one-on-one
meetings with Dr. Williams.
- Investors may register for the
conference here: https://investorsummitgroup.com/.
- 2021 LD Micro Invitational
Investor Conference: June 8-10, 2021
- Dr. Williams will deliver his
corporate presentation at 12:00pm ET on June 9, 2021.
- Investors may request one-on-one
meetings with Dr. Williams.
- Investors may register for the
conference here: https://ldmicrojune2021.mysequire.com/.
-
MarketsandMarkets 4th Annual Next Gen Immuno-Oncology
Virtual Congress-US Edition: June 28-30, 2021
- Dr. Williams will be speaking at
the scientific conference at 11:30am ET on June 29, 2021.
- The topic is “Personalized,
off-the-shelf cellular immunotherapy for cancer”.
- A copy of the presentation will be
posted
here: https://briacell.com/novel-technology/scientific-publications/.
- For additional information on the
conference and the speaker, please visit:
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers
Separately, BriaCell has recently appointed
Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and
Development. Since 2000, Dr. Lopez-Lago has been working as a
cancer scientist at Memorial Sloan-Kettering Cancer Center, New
York (MSKCC). Specifically, he has investigated various aspects of
tumor biology, including the development of targeted therapies for
Mesothelioma and the characterization of the biological mechanisms
underlying cancer metastasis. More recently, Dr. Lopez-Lago has
been interested in the study of the tumor immune-microenvironment
and in the development of immunotherapies for thoracic cancers
using chimeric antigen receptor (CAR) T cell technologies. Since
2013, Dr. Lopez-Lago has been working as Senior Research Scientist
at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in
Bio-Sciences and his doctorate in Molecular Biology from Santiago
of Compostela University, Spain.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Forward Looking Statements
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully in the section titled “Risk Factors” in the Company’s
SEC filings. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics
Corp. undertakes no duty to update such information except as
required under applicable law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
Company Contact:William V. Williams, MD
President &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public
RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Sep 2024 to Oct 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Oct 2023 to Oct 2024